Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
about
Combination therapies improve the anticancer activities of retinoids in neuroblastoma.Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids.Targeting of epigenetic regulators in neuroblastoma.
P2860
Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Thymosin-β4 is a determinant o ...... tion therapy in neuroblastoma.
@en
type
label
Thymosin-β4 is a determinant o ...... tion therapy in neuroblastoma.
@en
prefLabel
Thymosin-β4 is a determinant o ...... tion therapy in neuroblastoma.
@en
P2093
P2860
P50
P1433
P1476
Thymosin-β4 is a determinant o ...... ation therapy in neuroblastoma
@en
P2093
Belamy B Cheung
Daniel R Carter
Geraldine M O'Neill
Glenn M Marshall
Jessica Koach
Maria Kavallaris
Michael S Y Shum
Murray D Norris
Sela T Po'uha
P2860
P304
P356
10.1016/J.MOLONC.2015.04.005
P577
2015-04-29T00:00:00Z